Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 20261/30TDnetPDF(261KB)
Summary of Consolidated Financial Results for the Nine Months Ended December 31, 2025 [IFRS]1/30TDnetPDF(446KB)
米国血液学会(ASH)2025における開発中の抗がん剤enzomenib(DSP-5336)およびnuvisertib(TP-3654)に関する最新の臨床データ発表のお知らせ12/9TDnetPDF(246KB)
Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 202610/31TDnetPDF(270KB)
Summary of Consolidated Financial Results for the Second Quarter (First Half) of the Year Ending March 31, 2026 [IFRS]10/31TDnetPDF(464KB)
(Progress of Disclosure Matters) Confirmation of Gain on Sales of Shares of Subsidiaries in connection with the Company Split of Asian Business10/31TDnetPDF(149KB)
Sumitomo Pharma Announces Variances Between Its Financial Forecasts for the Half-Year Ended September 30, 2025, and Revisions to Financial Forecasts10/31TDnetPDF(207KB)
Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 20267/31TDnetPDF(278KB)
(Progress of Disclosure Matters) Completion of Procedures for Company Split of Asian Business and Share Transfer to Marubeni Global Pharma7/31TDnetPDF(176KB)
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2026 [IFRS]7/31TDnetPDF(548KB)